199 related articles for article (PubMed ID: 18183037)
1. The Biomarkers Consortium: on the critical path of drug discovery.
Altar CA
Clin Pharmacol Ther; 2008 Feb; 83(2):361-4. PubMed ID: 18183037
[TBL] [Abstract][Full Text] [Related]
2. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
3. The role of molecular imaging in drug discovery and development.
Hargreaves RJ
Clin Pharmacol Ther; 2008 Feb; 83(2):349-53. PubMed ID: 18167503
[TBL] [Abstract][Full Text] [Related]
4. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease.
Puntmann VO
Postgrad Med J; 2009 Oct; 85(1008):538-45. PubMed ID: 19789193
[TBL] [Abstract][Full Text] [Related]
5. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
[TBL] [Abstract][Full Text] [Related]
6. [Role of biomarkers in toxicity treatment "metabonomics" as a new biomarker discovery method].
Naraoka H; Suzumura K; Takeuchi K; Sasayama T
Rinsho Byori; 2008 Apr; 56(4):335-42. PubMed ID: 18516969
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in early cancer drug development: limited utility.
Glassman RH; Ratain MJ
Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
[TBL] [Abstract][Full Text] [Related]
8. Clinical biomarkers in drug discovery and development.
Frank R; Hargreaves R
Nat Rev Drug Discov; 2003 Jul; 2(7):566-80. PubMed ID: 12838269
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling in drug discovery and development.
Stratowa C; Wilgenbus KK
Curr Opin Mol Ther; 1999 Dec; 1(6):671-9. PubMed ID: 19629863
[TBL] [Abstract][Full Text] [Related]
10. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute.
Berridge BR; Pettit S; Walker DB; Jaffe AS; Schultze AE; Herman E; Reagan WJ; Lipshultz SE; Apple FS; York MJ
Am Heart J; 2009 Jul; 158(1):21-9. PubMed ID: 19540388
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
Carroll KJ
Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
[TBL] [Abstract][Full Text] [Related]
12. Challenges of cancer biomarker profiling.
Bensalah K; Montorsi F; Shariat SF
Eur Urol; 2007 Dec; 52(6):1601-9. PubMed ID: 17919807
[TBL] [Abstract][Full Text] [Related]
13. Genomic and genetic biomarkers of toxicity.
Mendrick DL
Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays.
Rai AJ
Expert Rev Mol Diagn; 2007 Sep; 7(5):545-53. PubMed ID: 17892363
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
Petersen TK
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
[TBL] [Abstract][Full Text] [Related]
17. Novel biomarkers of acute kidney toxicity.
Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive structural, functional, and molecular imaging in drug development.
Rudin M
Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067
[TBL] [Abstract][Full Text] [Related]
19. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
[TBL] [Abstract][Full Text] [Related]
20. Back to the future: driving innovation in drug development.
Wagner JA
Clin Pharmacol Ther; 2008 Feb; 83(2):199-202. PubMed ID: 18202681
[No Abstract] [Full Text] [Related]
[Next] [New Search]
